| 12.09 07:00 | Press Release: Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease |
| 12.09 07:00 | Press Release: Vivoryon Therapeutics N.V. Reports -2- |
| 12.09 07:00 | Press Release: Vivoryon Therapeutics N.V. Reports -3- |
| 12.09 07:00 | dpa-AFX: GNW-Adhoc: Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease |
| 05.09 18:12 | dpa-AFX: GNW-Adhoc: Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association |
| 05.09 18:12 | Press Release: Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association |
| 05.09 07:00 | Press Release: Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 |
| 18.07 07:00 | Press Release: Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease |
| 18.07 07:00 | Press Release: Vivoryon Therapeutics N.V. -2- |
| 18.07 07:00 | dpa-AFX: GNW-Adhoc: Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease |
| 09.07 07:00 | Press Release: Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease |
| 09.07 07:00 | dpa-AFX: GNW-Adhoc: Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease |
| 21.06 15:00 | Press Release: Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting |
| 21.06 15:00 | dpa-AFX: GNW-Adhoc: Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting |
| 23.05 07:00 | Press Release: Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease |
| 23.05 07:00 | Press Release: Vivoryon Therapeutics N.V. Reports -2- |
| 23.05 07:00 | dpa-AFX: GNW-Adhoc: Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease |
| 15.05 07:00 | Press Release: Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024 |
| 15.05 07:00 | dpa-AFX: GNW-Adhoc: Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024 |
| 08.05 07:00 | Press Release: Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024 |
|
|
